PTGX Q2 2019 Earnings — Protagonist Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

PTGXProtagonist Therapeutics, Inc.

$6B

Q2 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

-$8M-170.1% YoY

Gross Profit

-$11M133.9% margin

Operating Income

-$31M383.5% margin

Net Income

-$29M356.3% margin

EPS (Diluted)

$-1.18

QoQ Revenue Growth

-624.9%

Cash Flow

Operating Cash Flow

$4M

Free Cash Flow

$3M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$148M

Total Liabilities

$64M

Stockholders' Equity

$84M

Cash & Equivalents

$71M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	-$8M	$12M	-170.1%
Gross Profit	-$11M	$12M	-193.9%
Operating Income	-$31M	-$9M	-239.9%
Net Income	-$29M	-$9M	-236.8%